Definitive Healthcare Corp

Definitive Healthcare Corp. engages in the provision of healthcare commercial intelligence. Its solution offers information on healthcare providers and their activities to help the customers optimize from product development to go-to-market planning, sales, and marketing execution. The company was founded by Jason Kranzt in February 2011 and is headquartered in Framingham, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Definitive Healthcare reports robust Q4 performance amidst industry challenges

Definitive Healthcare's Q4 2022 performance reflects strong revenue growth and profitability, driven by strategic acquisitions and product innovations, despite economic headwinds.
Challenges such as extended deal cycles and macroeconomic impacts require adaptive strategies, while opportunities in data matching, client growth, and market expansion offer avenues for future success.
The company's focus on cost management, sales enhancements, and long-term growth in the healthcare data market positions it well for sustained performance and industry leadership.
Guidance for Q1 2023 underscores financial stability and growth potential, signaling a proactive approach to navigating challenges and seizing opportunities in the evolving healthcare landscape.

Definitive Healthcare Corp reports solid Q1 results amidst growth strategies

Definitive Healthcare Corp (DH) delivered solid Q1 results amidst challenges, with a focus on enhancing data capabilities and strategic M&A for future growth.
While facing higher churn and margin impacts, the company remains resilient, with stable pricing and a proactive approach to driving performance improvements.
Opportunities lie in acquisitions, cross-selling to existing clients, and maintaining a strong market position through innovation and client value creation.

Definitive Healthcare reports strong Q2 earnings, eyes AI opportunities

Definitive Healthcare's Q2 performance showcased revenue growth, EBITDA margin, and strategic acquisitions, despite workforce reductions and customer declines.
The company's strengths lie in tech investments, market share gains, and cross-sell opportunities, while challenges include workforce reductions and economic uncertainties.
Opportunities in AI advancements, long-term market prospects, and strategic investments position Definitive Healthcare for sustained growth and client value creation.

Definitive Healthcare Corp excels in Q3 amidst market challenges

Definitive Healthcare Corp's Q3 showcased strong financial performance, customer wins, and a focus on innovation despite market challenges.
The company's resilience, marketing effectiveness, and strategies to address churn position it well for future growth and success.
With a commitment to product development, customer engagement, and market leadership, Definitive Healthcare Corp navigates tough market conditions with adaptability.

Definitive Healthcare posts solid Q4 results, eyes growth opportunities in 2024

Definitive Healthcare's Q4 2023 performance was strong, with revenue growth, margin maintenance, and client base expansion.
The company's strategic focus on product investments, customer retention, and innovation positions it well for growth in 2024.
Challenges in the life sciences segment and high M&A valuations are being addressed through strategic initiatives and market positioning.
Opportunities in data asset investment, margin growth, and strong demand present avenues for continued success and expansion.

Definitive Healthcare reports mixed Q1 results, eyes growth opportunities

Definitive Healthcare's Q1 2024 Earnings Call showcased a resilient performance amidst challenges, with a focus on operational excellence and product innovation. Despite facing macroeconomic headwinds and restructuring disruptions, the company remains optimistic about long-term opportunities, driven by improving macro conditions and strategic initiatives.

Definitive Healthcare reports Q2 revenue growth, addresses sales challenges

Definitive Healthcare's Q2 2024 earnings call highlighted mixed performance, with a focus on addressing sales challenges and enhancing operational efficiency. CEO Coop emphasized growth, profitability, and strategic changes to drive shareholder value.

Definitive Healthcare reports Q3 results, plans for growth and efficiency

Definitive Healthcare's Q3 performance showed resilience despite revenue and EBITDA declines, with a strategic focus on simplification and customer success.
While facing challenges like high churn rates, the company aims for future growth through new product offerings and customer expansion.
Opportunities lie in operational efficiency improvements, share buyback program expansion, and strategic product integration for enhanced value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FRAMINGHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Founder, Interim CEO, and Executive Chairman, Jason Krantz, will present at the J.P. Morgan Global Technology, Media and Communications Conference.

Definitive Healthcare to Present at the 52nd Annual J.P. Morgan Global Technology, Media and Communications Conference

Definitive Healthcare (DH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over Definitive Healthcare (DH), Here's Why It's a 'Buy' Now

Definitive Healthcare Corp. (NASDAQ:DH ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Matthew Ruderman - Investor Relations Jason Krantz - Founder, Executive Chairman and Interim Chief Executive Officer Rick Booth - Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Jared Haase - William Blair Matt Shea - Needham & Company Anne Samuel - JPMorgan David Grossman - Stifel Stephanie Davis - Barclays Operator Welcome to Definitive Healthcare's Q1 2024 Earnings Call. Our host for today's call is Jason Krantz.

Definitive Healthcare Corp. (DH) Q1 2024 Earnings Call Transcript

Butterfly Network

Enovis Corp

Hims & Hers Health

Pulmonx

We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.

5 Medical Info Systems Stocks to Buy for Stable Returns

Definitive Healthcare Corp. (DH) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.06 per share a year ago.

Definitive Healthcare Corp. (DH) Matches Q1 Earnings Estimates

FRAMINGHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter ended March 31, 2024, on Tuesday, May 7, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

Definitive Healthcare Announces Timing of Its First Quarter 2024 Financial Results Conference Call and Webcast

Partnership offers solution to streamline engagement between pharmaceutical companies and KOLs to help increase the value of the clinical collaborations and conversations Partnership offers solution to streamline engagement between pharmaceutical companies and KOLs to help increase the value of the clinical collaborations and conversations

VML and Definitive Healthcare announce partnership to transform key opinion leader management

Definitive Healthcare stock is recommended as a buy due to strong long-term growth prospects and potential for margin expansion. Recent results show revenue growth in line with estimates and improved profitability, despite concerns about net dollar retention and customer churn. Management guidance supports a turnaround in FY25, with indicators of healthy organic demand and potential for growth acceleration.

Definitive Healthcare: Reiterate Buy Rating As I Expect Growth To Recover In FY25

FRAMINGHAM, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare  (Nasdaq:  DH ), an industry leader in healthcare commercial intelligence, today announced that it has been named one of the Boston Business Journal's Middle Market Leaders for 2024, a ranking of the 50 highest growth companies in Massachusetts. This marks the second year in a row that Definitive Healthcare has won this award.

Definitive Healthcare earns 2024 Middle Market Leader Award from Boston Business Journal

Definitive Healthcare Corp. (DH) Q4 2023 Earnings Call Transcript

Fourth quarter revenue grew 9% year-over-year to $65.9 million Full year 2023 revenue grew 13% year-over-year to $251.4 million  FRAMINGHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2023.

Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2023

FRAMINGHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2023, on Wednesday, February 28, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

Definitive Healthcare Announces Timing of Its Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast

After losing some value lately, a hammer chart pattern has been formed for Definitive Healthcare Corp. (DH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Definitive Healthcare Corp. (DH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Jason Krantz, Founder and Executive Chairman, to Serve as Interim CEO Company Reaffirms Fourth Quarter 2023 Guidance and Issues Preliminary Guidance for 2024 FRAMINGHAM, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH) (the “Company”), an industry leader in healthcare commercial intelligence, today announced that Robert Musslewhite has stepped down as Chief Executive Officer and as a member of the Board of Directors to transition to a new phase of leadership for the Company.

Definitive Healthcare Announces CEO Transition

Strengthening fundamentals: Definitive Healthcare shows steady revenue growth at 10% and expanding adjusted EBITDA margins. CRPO growth is slowing to a controlled rate and stabilizing, which indicates the end of client churn that took place over past 2 years. Valuation outlook: Fair price potential around $9.0, signaling a 25% upside from current $7.18.

Definitive Healthcare: Undervalued Vs. Peers Given Revenue Growth And Margin Expansion

Definitive Healthcare Corp. (DH) Q3 2023 Earnings Call Transcript

FRAMINGHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of Carrie Lazorchak as Definitive Healthcare's new Chief Revenue Officer, the Human Capital Management and Compensation Committee (the “Committee”) of Definitive Healthcare's Board of Directors granted Ms. Lazorchak an inducement award consisting of 385,695 time-based restricted stock units (“RSUs”) effective November 1, 2023. This award was individually negotiated and was granted as an inducement material to Ms. Lazorchak's commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).

Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

Definitive Healthcare Corp. (DH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Definitive Healthcare Corp. (DH) Soars 7.1%: Is Further Upside Left in the Stock?

FRAMINGHAM, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its third quarter ended September 30, 2023, on Thursday, November 2, 2023 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

Definitive Healthcare Announces Timing of Its Third Quarter 2023 Financial Results Conference Call and Webcast

FRAMINGHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that Carrie Lazorchak has been named Chief Revenue Officer, effective November 1, 2023.

Definitive Healthcare Names Carrie Lazorchak as Chief Revenue Officer

DH Q2 results were solid, with revenue in line and adjusted EBITDA slightly ahead. The company's near-term outlook is uncertain due to macroeconomic factors and extended sales cycles. Despite short-term challenges, the company's proprietary data competitive advantage positions it for long-term growth.

Definitive Healthcare: Fundamentals Remain Sound But Stock Sentiment Is Bad

FRAMINGHAM, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced two changes to its Board of Directors. On September 6, 2023, Scott Stephenson, the former Chief Executive Officer of Verisk Analytics, joined the Board of Directors and the nominating and corporate governance committee of the Board, while Chris Mitchell, managing director of Spectrum Equity, stepped down from the Board of Directors.

Definitive Healthcare Welcomes Scott Stephenson to Board of Directors

FRAMINGHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Executive Officer, Robert Musslewhite, and its Chief Financial Officer, Rick Booth, will present at the Morgan Stanley 21st Annual Global Healthcare Conference.

Definitive Healthcare to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ: DH). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Definitive Healthcare Corp. - DH

Definitive Healthcare Corp. (NASDAQ:DH ) Q2 2023 Results Conference Call August 14, 2023 5:00 PM ET Company Participants Matt Ruderman - Chief Legal Officer Robert Musslewhite - Chief Executive Officer Jason Krantz - Founder and Executive Chairman Rick Booth - Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Matt Shea - Needham & Company Brian Peterson - Raymond James Allen Lutz - Bank of America David Grossman - Stifel Jonathan Yong - Credit Suisse George Hill - Deutsche Bank Operator Welcome to the Definitive Healthcare Q2 2023 Earnings Call. Our host for today's call is Robert Musslewhite.

News for Definitive Healthcare Corp Stock (DH)